Opinion - (2025) Volume 13, Issue 4
Received: 04-Aug-2025, Manuscript No. jcdd-25-176818;
Editor assigned: 06-Aug-2025, Pre QC No. P-176818;
Reviewed: 20-Aug-2025, QC No. Q-176818;
Revised: 25-Aug-2025, Manuscript No. R-176818;
Published:
01-Sep-2025
, DOI: 10.37421/2329-9517.2025.13.684
Citation: Mei Lin. ”Beta-blockers: Diverse Uses, Benefits, and
Challenges.” J Cardiovasc Dis Diagn 13 (2025):684.
Copyright: © 2025 L. Mei This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution
and reproduction in any medium, provided the original author and source are credited.
This article offers a comprehensive look at the role of beta-blockers in managing heart failure with reduced ejection fraction, highlighting the impact of recent clinical trials and updated guideline recommendations. It emphasizes the importance of initiating and uptitrating beta-blocker therapy to target doses for optimal patient outcomes, discussing specific agents and their evidence base [1].
This review delves into the evolving role of beta-blockers in hypertension management, addressing both recent findings and persistent debates. It highlights specific patient populations who benefit most from these agents and discusses their comparative efficacy and safety profiles against other antihypertensive classes, offering a balanced perspective on their contemporary use [2].
This article examines the contemporary utility of beta-blockers in managing atrial fibrillation, focusing on their efficacy in rate control and rhythm management. It integrates current guidelines and clinical evidence to provide a practical overview of how these agents fit into modern treatment strategies for various AF presentations [3].
This contemporary review explores the complex and often debated role of perioperative beta-blocker administration in patients undergoing non-cardiac surgery. It summarizes current evidence regarding risk stratification, initiation, and continuation strategies, aiming to clarify when and how these medications can optimize outcomes while minimizing adverse events in the surgical setting [4].
This systematic review evaluates the evidence supporting the use of beta-blockers in managing various anxiety disorders. It assesses their efficacy in reducing somatic symptoms of anxiety, such as palpitations and tremors, and discusses their role as an adjunctive therapy, particularly in performance anxiety and generalized anxiety, while considering potential side effects and patient suitability [5].
This review explores the current landscape of pharmacological treatments for migraine, including the well-established role of beta-blockers in prophylaxis. It discusses their mechanism of action in migraine prevention, clinical efficacy, and practical considerations for their use, while also touching upon newer therapeutic agents and future directions in migraine management [6].
This updated overview provides a comprehensive analysis of the adverse effects associated with beta-blocker therapy, covering both common and less frequent reactions across various organ systems. It discusses the mechanisms underlying these side effects and offers guidance on patient selection, monitoring, and strategies to mitigate adverse events, ensuring safer and more effective use of these widely prescribed drugs [7].
This review provides a contemporary look at the clinical pharmacology and therapeutic applications of various beta-blockers. It differentiates between selective and non-selective agents, highlighting their distinct pharmacological properties and how these translate into specific clinical indications, efficacy, and side effect profiles across a range of cardiovascular conditions [8].
This critical appraisal examines the evidence for beta-blocker use in heart failure with preserved ejection fraction (HFpEF), a condition where their benefit is less clear than in HFrEF. It reviews clinical trial data, discusses potential mechanisms of action, and highlights the ongoing need for more definitive evidence to guide their routine prescription in this challenging patient population [9].
This article provides an updated perspective on the role of beta-blockers in peripheral artery disease (PAD), addressing historical concerns and presenting contemporary evidence. It emphasizes that beta-blockers are generally safe and often beneficial in PAD patients, especially those with co-existing coronary artery disease or hypertension, debunking old myths and promoting evidence-based prescribing practices [10].
This review provides a contemporary look at the clinical pharmacology and therapeutic applications of various beta-blockers. It differentiates between selective and non-selective agents, highlighting their distinct pharmacological properties and how these translate into specific clinical indications, efficacy, and side effect profiles across a range of cardiovascular conditions [8].
This article offers a comprehensive look at the role of beta-blockers in managing heart failure with reduced ejection fraction, highlighting the impact of recent clinical trials and updated guideline recommendations. It emphasizes the importance of initiating and uptitrating beta-blocker therapy to target doses for optimal patient outcomes, discussing specific agents and their evidence base [1]. This review delves into the evolving role of beta-blockers in hypertension management, addressing both recent findings and persistent debates. It highlights specific patient populations who benefit most from these agents and discusses their comparative efficacy and safety profiles against other antihypertensive classes, offering a balanced perspective on their contemporary use [2].
This article examines the contemporary utility of beta-blockers in managing atrial fibrillation, focusing on their efficacy in rate control and rhythm management. It integrates current guidelines and clinical evidence to provide a practical overview of how these agents fit into modern treatment strategies for various AF presentations [3]. This article provides an updated perspective on the role of beta-blockers in peripheral artery disease (PAD), addressing historical concerns and presenting contemporary evidence. It emphasizes that beta-blockers are generally safe and often beneficial in PAD patients, especially those with co-existing coronary artery disease or hypertension, debunking old myths and promoting evidence-based prescribing practices [10].
This contemporary review explores the complex and often debated role of perioperative beta-blocker administration in patients undergoing non-cardiac surgery. It summarizes current evidence regarding risk stratification, initiation, and continuation strategies, aiming to clarify when and how these medications can optimize outcomes while minimizing adverse events in the surgical setting [4].
This systematic review evaluates the evidence supporting the use of beta-blockers in managing various anxiety disorders. It assesses their efficacy in reducing somatic symptoms of anxiety, such as palpitations and tremors, and discusses their role as an adjunctive therapy, particularly in performance anxiety and generalized anxiety, while considering potential side effects and patient suitability [5]. This review explores the current landscape of pharmacological treatments for migraine, including the well-established role of beta-blockers in prophylaxis. It discusses their mechanism of action in migraine prevention, clinical efficacy, and practical considerations for their use, while also touching upon newer therapeutic agents and future directions in migraine management [6].
This updated overview provides a comprehensive analysis of the adverse effects associated with beta-blocker therapy, covering both common and less frequent reactions across various organ systems. It discusses the mechanisms underlying these side effects and offers guidance on patient selection, monitoring, and strategies to mitigate adverse events, ensuring safer and more effective use of these widely prescribed drugs [7]. This critical appraisal examines the evidence for beta-blocker use in heart failure with preserved ejection fraction (HFpEF), a condition where their benefit is less clear than in HFrEF. It reviews clinical trial data, discusses potential mechanisms of action, and highlights the ongoing need for more definitive evidence to guide their routine prescription in this challenging patient population [9].
Beta-blockers are a foundational class of drugs with diverse therapeutic applications, primarily in cardiovascular medicine. They are critical for managing heart failure with reduced ejection fraction, where guidelines emphasize their initiation and uptitration for optimal outcomes. In hypertension, beta-blockers offer a balanced perspective, with ongoing debates and new findings shaping their use in specific patient populations. Their utility extends to controlling heart rate and managing rhythm in atrial fibrillation, integrating current clinical evidence. Beyond cardiac conditions, beta-blockers play a role in migraine prophylaxis and are evaluated for reducing somatic anxiety symptoms, serving as an adjunctive therapy in anxiety disorders like performance and generalized anxiety. Contemporary evidence also supports their generally safe and beneficial use in peripheral artery disease, especially for patients with co-existing conditions, debunking older concerns. The perioperative administration of beta-blockers in non-cardiac surgery remains a complex area, requiring careful risk stratification to optimize outcomes. Understanding the clinical pharmacology, including the differentiation between selective and non-selective agents, is key to appreciating their distinct indications and side effect profiles. While widely used, a comprehensive analysis of their adverse effects and strategies to mitigate them is crucial. It's also important to note the less clear benefit in conditions like heart failure with preserved ejection fraction, highlighting areas for continued research to guide their precise application.
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Cardiovascular Diseases & Diagnosis received 427 citations as per Google Scholar report
